WCLC 2024 Review: MARIPOSA Trial - Extended Follow Up and Patient Relevant Outcomes of Amivantamab + Lazertinib vs. Osimertinib in 1L EGFRm NSCLC | VuMedi

Find latest Non-Small Cell Lung Cancer videos · 600+ videos

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

10 seconds

Playback speed

ecancer

WCLC 2024 Review: MARIPOSA Trial - Extended Follow Up and Patient Relevant Outcomes of Amivantamab + Lazertinib vs. Osimertinib in 1L EGFRm NSCLC

By ecancer FEATURING Enriqueta Felip

By ecancer FEATURING Enriqueta Felip

203 views

January 16, 2025

Comments 0

Login to view comments. Click here to Login